Advertisement

Hydergine: Interaction with Neurotransmitter Systems in the Central Nervous System

  • Rudolf Markstein

Abstract

Hydergine (co-dergocrine, ergoloid mesylates, dihydroergotoxine) is an ergot preparation shown to be of value in the treatment of senile mental impairment.

Inexperimental animals, Hydergine induces behaviors suggesting an influence on monoaminergic systems. Results from biochemical in vitro studies indicate that Hydergine has multiple effects and interacts directly with α-adrenoceptors, dopamine (DA), and serotonin (5-TH) receptor subtypes. In rat cortex slices, it blocks noradrenaline (NA)-induced cyclic adenosine monophosphate (cAMP) formation and facilitates evoked NA release. This indicates antagonistic effects at α 1 - and α 2 - adrenoceptors. Furthermore, Hydergine has mixed agonistic/antagonistic effects at postsynaptic DA receptors, stimulating adenylate cyclase and inhibiting action-potential-evoked acetylcholine release in the rat striatum. Also, at presynaptic DA receptors inhibiting evoked DA release in the rat striatum, Hydrergine has mixed agonistic/antagonistic effects.

Moreover, Hydergine was found to have mixed agonistic/antagonistic effects on 5-HT receptors involved in stimulating adenylate cyclase activity in homogenates of rat hippocampus. In slices of rat hippocampus, Hydergine enhanced electrically evoked acetylcholine release. Based on these findings, it is suggested that Hydergine can various transmitter systems in the central nervous system.

Keywords

Adenylate Cyclase Ergot Alkaloid Monoaminergic System Cortex Slice Tritium Overflow 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Adolfsson, R., Gottfries, C.G,. Roos, B.E., and Winblad, B.: Post-mortem distribution of dopamine and homovanillic acid in human brain, variations related to age, and a review of the literature. J. Neural Transm. 45, 81–105 (1979).PubMedCrossRefGoogle Scholar
  2. Anden, N.E., Carlsson, A., and Haggendal, J.: Adrenergic mechanisms. Ann. Rev. Pharmacol 9, 119–134 (1969).PubMedCrossRefGoogle Scholar
  3. Azmitia, E.C.: The serotonin-producing neurons of the midbrain median and dorsal raphe nuclei. In Handbook of Psychopharmacology, Vol. 9, pp. 233–314. New York, Plenum, 1978.Google Scholar
  4. Beart, P.: Multiple dopamine receptors—new vistas. Trends in Pharmacol Sci. 5, 100–102 (1982).CrossRefGoogle Scholar
  5. Berthelsen, S., and Pettinger, W.A.: A functional basis for classification of a- adrenergic receptors. Life Sci. 21, 595–606 (1977).PubMedCrossRefGoogle Scholar
  6. Biirki, H.R., Asper, H., Ruch, W., and Ziiger, P.E.: Bromocriptine, dihydro-ergotoxine, methysergide, d-LSD, CF 25-397 and 29-712: Effects on the metabolism of the biogenic amines in the brain of the rat. Psychopharmacology 57, 221–237 (1978).Google Scholar
  7. Carlsson, A.: Age-dependent changes in central dopaminergic and other mono- aminergic systems. Adv. Exp. Med. Bio. 113, 1–13 (1978).Google Scholar
  8. Carlsson, A., Adolfson, R., Aquilonius, S.M., Gottfries, C.G., Orland, L., Svennerholm, L., and Winblad, B.: Biogenic amines in human brain in normal aging, senile dementia and chronic alcoholism. In Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects, pp. 295–304. New York: Raven, 1979.Google Scholar
  9. Closse, A., Frick, W., Hauser, D., and Sauter, A.: Characterisation of 3H- bromocriptine binding to calf caudate membranes. In Psychopharmacology and Biochemistry of Neurotransmitter Receptors, pp. 463–474. New York: Elsevier/North Holland, 1980.Google Scholar
  10. Cools, A.R., and Van Rossum, J.M.: Multiple receptors for brain dopamine in behavior regulation: Concept of dopamine-E and dopamine-J receptors. Life Sci. 27, 1237–1253 (1980).PubMedCrossRefGoogle Scholar
  11. Daly, J.W., Padgett, W., Creveling, C.R., Cantacuzene, D., and Kirch, K.L.: Cyclic AMP generating systems: Regional differences in activation by adrenergic receptors in rat brain. J. Neurosci. 1, 49–59 (1981).PubMedGoogle Scholar
  12. Dravid, A.R.: Deficits in cholinergic enzymes and muscarinic receptors in the hippocampus and striatum of senescent rats. Effect of chronic Hydergine treatment. Arch. Int. Pharmacodyn. Ther. 264, 195–202 (1983).PubMedGoogle Scholar
  13. Engel, G., Gothert, M., Miiller-Schweinitzer, E., Schlicker, E., Sistonen, L., and Stadler, P.A.: Evidence for common pharmacological properties of [3H]5- hydroxytryptamine binding sites, presynaptic 5-hydroxytryptamine autorecep- tors in CNS and inhibitor presynaptic 5-hydroxytryptamine receptors on sympathetic nerves. Naunyn-Schmiedebergs Arch. Pharmacol 324, 116–124 (1983).PubMedCrossRefGoogle Scholar
  14. Garau, L., Govani, S., Stefanini, E., Trabucchi, M., and Spano, P.F.: Dopamine receptors: Pharmacological and anatomical evidences indicate that two distinct dopamine receptor populations are present in rat striatum. Life Sci. 23, 1745–1750 (1978).PubMedCrossRefGoogle Scholar
  15. Goldstein, M., Lew, J.Y., Hata, F., and Lieberman, A.: Binding interactions of ergot alkaloids with monoaminergic receptors in the brain. Gerontology 24(Suppl. 1), 76–85 (1978).PubMedCrossRefGoogle Scholar
  16. Gottfries, C.G.: The metabolism of some neurotransmitters in aging and dementia disorders. Gerontology 28(Suppl. 2), 11–19 (1982).PubMedCrossRefGoogle Scholar
  17. Helmreich, J., Reimann, W., Hertting, G., and Starke, K.: Are presynaptic dopamine autoreceptors and postsynaptic dopamine receptors in the rabbit caudate nucleus pharmacologically different? Neuroscience 7, 1559–1566 (1982).PubMedCrossRefGoogle Scholar
  18. Jouvet, J.: The role of monoamines and acetylcholine containing neurons in the regulation of the sleep-waking cycle. Erg. Physiol. 64, 166–307 (1972).PubMedGoogle Scholar
  19. Kebabian, J.W., and Calne, D.B.: Multiple receptors for dopamine. Nature 211, 93–96 (1979).CrossRefGoogle Scholar
  20. Loew, D., Vigouret, J.M., and Jaton, A.L.: Neuropharmacological investigations with two ergot alkaloids, Hydergine and bromocriptine. Postgrad. Med. J. 52(Suppl. 1), 40–46 (1976).PubMedGoogle Scholar
  21. Loew, D.M., and Vigouret, J.M.: Neuropharmakologische Charakterisierung von Dihydroergotoxin (Hydergin). In Mutterkornalkaloide heute, pp. 69–79. Stuttgart: Georg Thieme, 1982.Google Scholar
  22. Loew, D., and Weil, C.: Hydergine® in senile mental impairment. Gerontology 28, 54–74 (1982).PubMedCrossRefGoogle Scholar
  23. Markstein, R., and Wagner, H.: Effect of dihydroergotoxine on cyclic AMP generating systems in rat cerebral cortex slices. Gerontology 24(Suppl. 1), 94–105 (1978).PubMedCrossRefGoogle Scholar
  24. Markstein, R.: Dopamine receptor profile of Co-dergocrine (Hydergine®) and its components. European J. Pharmacol. 86, 145–155 (1983a).CrossRefGoogle Scholar
  25. Markstein, R.: Co-dergocrine has multiple effects on monoaminergic neuro-transmission. Fed. Proc. 42, 496 (1983b).Google Scholar
  26. Markstein, R., Closse, A., and Frick, W.: Interaction of ergot alkaloids and their combination (Co-dergocrine) with a-adrenoceptors in the CNS. European J. Pharmacol. 93, 156–169 (1983).CrossRefGoogle Scholar
  27. McGeer, E.G., and McGeer, P.L.: Neurotransmitter metabolism in the aging brain. In Neurobiology of Aging, pp. 389–403. New York: Raven, 1976.Google Scholar
  28. McGeer, E.G.: Neurotransmitter systems in aging and senile dementia. Progr. Neuro-Psychopharmacol. 5, 435–445 (1981).CrossRefGoogle Scholar
  29. Nieuwenhuys, R., Voogd, J., and Van Huijzen, Chr.: The Human Central Nervous System. Berlin: Springer-Verlag, 1978.Google Scholar
  30. Olpe, H.R., and Steinmann, M.W.: The effect of vincamine, Hydergine and piracetom on the firing rate of Locus coeruleus neurons. Behav. Neural. Biol. 33, 249–251 (1982).CrossRefGoogle Scholar
  31. Peroutka, S.J., and Snyder, S.H.: Multiple serotonin receptors: Differential binding of [3H] serotonin, [3H]lysergic acid diethylamide and [3H] spiroperidol. Molec. Pharmacol 16, 687–699 (1979).Google Scholar
  32. Peroutka, S.J., Lebowitz, R.M., and Snyder, S.H.: Two distinct central serotonin receptors with different physiological functions. Science 212, 827–829 (1979).CrossRefGoogle Scholar
  33. Pradhan, S.N.: Central neurotransmitter and aging. Life Sci. 26, 1643–1656 (1980).Google Scholar
  34. Reader, T.A., Ferron, A., Descanies, L., and Jasper, H.H.: Modulatory role of biogenic amines in the cerebral cortex. Microiontophoretic studies. Brain Res. 160, 217–229 (1979).PubMedCrossRefGoogle Scholar
  35. Schild, H.O.: pA and competitive drug antagonism. Br. J. Pharmacol 4, 277–280 (1949).Google Scholar
  36. Starke, K.: Regulation of noradrenaline release by presynaptic receptor systems. Rev. Physiol Biochem. Pharmacol 77, 1–124 (1977).PubMedCrossRefGoogle Scholar
  37. Starke, K., Reimann, W., Zumstein, A., and Hertting, G.: Effect of dopamine agonists and antagonists on release of dopamine in the rabbit caudate nucleus in vitro. Naunyn-Schmiedebergs Arch. Pharmacol 305, 27–36 (1978).PubMedCrossRefGoogle Scholar
  38. Stoof, J.C., Thieme, R.E., Vrijmoed-De Vries, M.C., and Mulder, A.H.: In vitro acetylcholine release from rat caudate nucleus as a new model for testing drugs with dopamine receptor activity. Naunyn-Schmiedebergs Arch. Pharmacol 309, 119–124 (1979).PubMedCrossRefGoogle Scholar
  39. U’Prichard, D.C., Greenberg, D.A., and Snyder, S.H.: Binding characteristics of a radiolabeled agonist and antagonist at central nervous system. Alpha- noradrenergic receptors. Mol. Pharmacol 21, 454–473 (1977).Google Scholar
  40. Venn, R.D.: Clinical pharmacology of ergot alkaloids in senile cerebral insuf-ficiency. In Ergot Alkaloids and Related Compounds, pp. 533–566. New York: Springer-Verlag, 1978.Google Scholar
  41. Vigouret, J.M., Biirki, H.R., Jaton, A.L., Ziiger, P.E., and Loew, D.M.: Neuro-chemical and neuropharmacological investigations with four ergot derivatives: Bromocriptine, dihydroergotoxine, CF 25-397 and CM 29-712. Pharmacology 16(Suppl. 1), 156–173 (1978).PubMedCrossRefGoogle Scholar
  42. Vigouret, J.M., Jaton, A.L., and Loew, D.: Increased sensitivity after repeated administration of ergot derivatives in rats. Experientia 35, 953 (1979).Google Scholar
  43. Woodward, C., Moises, H.C., Waterhouse, P.D., Hoffer, B., and Freedman, R.: Modulatory actions of norepinephrine in the central nervous system. Fed. Proc. 38, 2109–2116 (1979).PubMedGoogle Scholar
  44. Züer, P.E., Vigouret, J.M., and Loew, D.M.: Inhibition of reserpine-induced PGO-waves in the cat by ergot derivatives. Experientia 34, 637–639 (1978).PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1985

Authors and Affiliations

  • Rudolf Markstein

There are no affiliations available

Personalised recommendations